Overview of the drug development pipeline for rabies
Rabies is a viral disease that results in acute irritation of the brain in humans and other animals. This disease is spread from humans to animals such as dogs, cats, and cows. The saliva from an infected animal results in spreading rabies on contact with a human body part. Infected individuals offer symptoms such as incubation, prodrome, acute neurologic pain, and coma. These individuals are offered therapeutic treatments such as rabies immune globulin or series of rabies vaccine. In the last decade, US witnessed only 8 cases of human rabies in the US due to the extensive dog rabies vaccination programs conducted that stopped the natural spread of rabies among domestic dogs. With the increasing incidences of diseased mammals that are unvaccinated and infected due to contaminated wildlife, Technavio’s market research analysts have forecasted the extensive investment and drug development for suitable therapeutics for rabies in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage followed by pre-clinical stage. Our market research analysts have also identified that similar amount of drug molecules are under the phase III and phase II drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I, phase I/II, and phase II/III stage.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of rabies. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- PROSETTA BIOSCIENCES
- SYNERMORE BIOLOGIC
- VBI VACCINE
Therapeutic assessment of the drug development pipeline for rabies by route of administration
- Intradermal
- Intradermal/intramuscular
- Intramuscular
In the intramuscular route of administration (ROA), drug substances are administered within a muscle. It has been observed that the majority of therapeutics for rabies are being developed for intramuscular administration.
Therapeutic assessment of the drug development pipeline for rabies by therapies employed
- Monotherapy
- Combination
According to this pipeline analysis report, majority of the therapies employed are being developed in the form of monotherapy. In the monotherapy employed in this pipeline, a single drug is used to treat a particular disorder.
Technavio also offers customization on reports based on specific client requirement.